Dr. David W. Cleaver, D.O.

Medicare patients and services

Medicare patients, 2024

1,794

Services billed

20,218

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 23 companies reported 186 payments worth $59,540 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Missouri →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $99,009 in research payments for these studies, mostly to the institutions running them.

• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderat…
  Janssen Research & Development, LLC
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Mod…
  Janssen Research & Development, LLC
• Observation priority e short - lebrikizumab - atopic dermatitis
  Eli Lilly and Company
• A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
  AbbVie Inc. · Active, not recruiting · NCT05889182
• Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
  Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT03428646

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Dermatology clinicians in Kirksville

• Benjamin E. Adams, D.O.
• Jonathan L. Cleaver, D.O.
• Lloyd J. Cleaver, DO
• Baydon E. Hilton
• Emily Kollmann, D.O., M.S.
• Nicholas Noyce, DO